Intra-aortic balloon counterpulsation and delayed revascularization for myocardial infarction and shock in the absence of primary angioplasty: A treatment strategy with or without thrombolysis?

Coronary Artery Disease

Volumn 19, Issue 7, 2008, Pages 521-526

  Drakos, Stavros G ^a   Anastasiou Nana, Maria I ^b   Terrovitis, John V ^a   Tsagalou, Eleftheria P ^a   Kanakakis, John ^b   Ntalianis, Argirios ^a   Lazaris, Nikolaos ^b   Maroulidis, George ^a   Venetsanakos, John ^a   Bonios, Michael ^a   Nanas, John N ^a,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Acute myocardial infarction; Cardiogenic shock; Intra aortic balloon counterpulsation; Thrombolytic therapy

Indexed keywords

DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FIBRINOLYTIC AGENT; MIDAZOLAM; MORPHINE; NORADRENALIN;

ADULT; AGED; AORTA BALLOON; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CONTROLLED STUDY; COUNTERPULSATION; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAAORTIC BALLOON COUNTERPULSATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTRA-AORTIC BALLOON PUMPING; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PATIENT TRANSFER; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 55749086030     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283109011     Document Type: Review

References (37)

1. Duvernoy CS, Bates ER. Management of cardiogenic shock attributable to acute myocardial infarction in the reperfusion era. J Intensive Care Med 2005; 20:188-198.
2. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med 1999; 341:625-634.
3. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2004; 44:E1-E211.
4. Sanborn TA, Sleeper LA, Bates ER, Jacobs AK, Boland J, French JK, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36:1123-1129.
5. Ohman EM, Hochman JS. Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit? Am Heart J 2001; 141:889-892.
6. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous treatment in acute myocardial infarction. Lancet 1986; 1:397-402.
7. Fibrinolytic Therapy Trialists' (FTT) Collaborative Study Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-322.
8. Prewitt RM, Gu S, Schick U, Ducas J. Effect of a mechanical vs a pharmacologic increase in aortic pressure on coronary blood flow and thrombolysis induced by IV administration of a thrombolytic agent. Chest 1997; 111:449-453.
9. Gurbel PA, Anderson RD, MacCord CS, Scott H, Komjathy SF, Poulton J, et al. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. Circulation 1994; 89:361-365.
10. Nanas JN, Moulopoulos SD. Counterpulsation: historical background, technical improvements, hemodynamic and metabolic effects. Cardiology 1994; 84:156-167.
11. Anderson RD, Ohman EM, Holmes DR Jr, Col I, Stebbins AL, Bates ER, et al. Use of intra-aortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the GUSTO-I Study. J Am Coll Cardiol 1997; 30:708-715.
12. Waksman R, Weiss AT, Gotsman MS, Hasin Y. Intra-aortic counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J 1993; 14:1-74.
13. Moulopoulos S, Stamatelopoulos S, Petrou P. Intra-aortic balloon assistance in intractable cardiogenic shock. Eur Heart J 1986; 7:396-403.
14. Kovack PJ, Rasak MA, Bates ER, Ohman EM, Stomel RJ. Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. J Am Coll Cardiol 1997; 29:1454-1458.
15. Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, et al. Investigators in the National Registry of Myocardial Infarction 2. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001; 141:933-939.
16. Moulopoulos SD, Stamatelopoulos SF, Nanas JN, Kontoyannis DA, Nanas SN. Effect of protracted dobutamine infusion on survival of patients in cardiogenic shock treated with intra-aortic balloon pumping. Chest 1993; 103:248-252.
17. Sanborn TA, Feldman T. Management strategies for cardiogenic shock. Curr Opin Cardiol 2004; 19:608-612.
18. Hochman JS. Cardiogenic shock complicating acute myocardial infarction. Expanding the paradigm. Circulation 2003; 107:2998-3002.
19. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? One-year survival following early revascularization for cardiogenic shock. J Am Med Assoc 2001; 285:190-192.
20. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336:71-75.
21. Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, et al. For the GUSTO-I investigators. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I Trial Experience. J Am Coll Cardiol 1995; 26:668-667.
22. Bates ER, Topol EJ. Limitations of thromborytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991; 18:1077-1084.
23. Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992; 20:1626-1633.
24. Ohman EM, Topol EJ, Califf RM, Bates ER, Elus SG, Kereiakes DJ, et al. An analysis of the cause of early mortality after administration of thrombolytic therapy. Coron Artery Dis 1993; 4:957-964.
25. Gu S, Ducas J, Patton JN, Greenberg D, Prewitt RM. Coronary thrombolysis: comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase. Chest 1992; 101:1684-1690.
26. Nanas JN, Nanas SN, Kontoyannis DA, Moussoutzani KS, Hatzigeorgiou JP, Heras PB, et al. Myocardial salvage by the use of reperfusion and intra-aortic balloon pump: Experimental Study. Ann Thorac Surg 1996; 61:629-634.
27. Kern MJ, Aguirre FV, Tatineni S, Penick D, Serota H, Donohue T, et al. Enhanced coronary blood flow velocity during intra-aortic balloon counterpulsation in critically ill patients. J Am Coll Cardiol 1993; 21:359-368.
28. Pierrakos Ch, Chantos Ch, Terrovitis J, Dolou P, Argiriou M, Glentis P, et al. Intra-aortic balloon counterpulsation increased coronary blood flow during reperfusion in an ischemia/reperfusion experimental model but not in the intact heart. Eur Heart J 2004; 25:188. (Abstract).
29. Terrovitis J, Charitos Ch, Pierrakos Ch, Tsolakis E, Charitos E, Glentis P, et al. Intra-aortic balloon counterpulsation decreased the extent of the no-reflow phenomenon and infarct size in an ischemia/reperfusion experimental model Eur Heart J 2004; 25:191. (Abstract).
30. Nanas J, Tsolakis E, Terrovits J, Eleftheriou A, Drakos S, Dalianis A, et al. Moderate systolic hypotension during reperfusion reduces the coronary blood flow and increases the size of myocardial infarction in pigs. Chest 2004; 125:1492-1499.
31. Ohman EM, Nanas J, Stomel RJ, Leesar MA, Nielsen DW, O'Dea D, et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: Results of the TACTICS Trial. J Thromb Thrombolys 2005; 19:33-39.
32. Norell MS. Randomized trials in cardiogenic shock: what's the problem? Eur Heart J 1999; 20:987-988.
33. O'Rourke MF, Norris RM, Campbell TJ, Chang VP, Sammel NL. Randomized controlled trial of intra-aortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J Cardiol 1981; 47:815-820.
34. Flaherty JT, Becker LC, Weiss JL, Brinker JA, Bulkley BH, Gerstenblith G, et al. Results of a randomized prospective trial of intra-aortic balloon counterpulsation and intravenous nitroglycerin in patients with acute myocardial infarction. J Am Coll Cardiol 1985, 6:434-446.
35. Hudson MP, Granger CB, Stebbins AL, White HD, Bates ER, Greenbaum AB, et al. Cardiogenic shock survival and use of intra-aortic balloon counterpulsation: results from the GUSTO I and III trials. Circulation 1999; 100 (Suppl):I:370.
36. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367:569-578.
37. Ohman EM, Califf RM, George BS, Quigley PJ, Kereiakes DJ, Harrelson-Woodlief L, et al. The use of intra-aortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. Am Heart J 1991; 121:895-901.